Pacer Advisors Portfolio holdings
AUM
$39.6B
1-Year Return
5.04%
This Quarter Return
+6.36%
1 Year Return
+5.04%
3 Year Return
+42.86%
5 Year Return
+91.64%
10 Year Return
+332.32%
AUM
$5.75B
AUM Growth
+$430M
(+8.1%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-18.82%
Top 10 Holdings %
Top 10 Hldgs %
27.15%
Holding
1,587
New
76
Increased
379
Reduced
937
Closed
183
Top Buys
| 1 |
HP
HPQ
|
+$6.72M |
| 2 |
Newmont
NEM
|
+$6.32M |
| 3 |
General Mills
GIS
|
+$6.24M |
| 4 |
TJX Companies
TJX
|
+$5.82M |
| 5 |
Ford
F
|
+$5.76M |
Top Sells
| 1 |
Iron Mountain
IRM
|
+$16.2M |
| 2 |
Apple
AAPL
|
+$15.9M |
| 3 |
Amazon
AMZN
|
+$14.5M |
| 4 |
Microsoft
MSFT
|
+$13.1M |
| 5 |
GDS Holdings
GDS
|
+$7.93M |
Sector Composition
| 1 | Real Estate | 17.47% |
| 2 | Technology | 14.61% |
| 3 | Consumer Discretionary | 9.29% |
| 4 | Healthcare | 7.36% |
| 5 | Communication Services | 6.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1226
Ambev
ABEV
$35.7B
| $71K | ﹤0.01% |
25,915
+9,688
| +60% | +$26.5K |
|
1227
Editas Medicine
EDIT
$244M
| $71K | ﹤0.01% |
1,682
-450
| -21% | -$19K |
|
|
ARNA
1228
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $70K | ﹤0.01% |
1,010
-896
| -47% | -$62.1K |
|
|
BPMC
1229
DELISTED
Blueprint Medicines
BPMC
| $70K | ﹤0.01% |
724
-428
| -37% | -$41.4K |
|
1230
Kodiak Sciences
KOD
$524M
| $70K | ﹤0.01% |
613
-426
| -41% | -$48.6K |
|
1231
Mersana Therapeutics
MRSN
$37.3M
| $70K | ﹤0.01% |
173
+3
| +2% | +$1.21K |
|
1232
Replimune Group
REPL
$469M
| $70K | ﹤0.01% |
2,288
-116
| -5% | -$3.55K |
|
|
VXRT
1233
DELISTED
Vaxart
VXRT
| $70K | ﹤0.01% |
11,566
-6,220
| -35% | -$37.6K |
|
|
NVTA
1234
DELISTED
Invitae Corporation
NVTA
| $70K | ﹤0.01% |
1,828
-502
| -22% | -$19.2K |
|
|
MRTX
1235
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $70K | ﹤0.01% |
408
-146
| -26% | -$25K |
|
1236
America Movil
AMX
$61B
| $69K | ﹤0.01% |
5,061
+1,987
| +65% | +$27.1K |
|
1237
Denali Therapeutics
DNLI
$2.17B
| $69K | ﹤0.01% |
1,204
-452
| -27% | -$25.9K |
|
1238
Precision BioSciences
DTIL
$58.9M
| $69K | ﹤0.01% |
221
+103
| +87% | +$32.2K |
|
1239
Inovio Pharmaceuticals
INO
$141M
| $69K | ﹤0.01% |
619
-378
| -38% | -$42.1K |
|
1240
Iovance Biotherapeutics
IOVA
$876M
| $69K | ﹤0.01% |
2,187
-458
| -17% | -$14.5K |
|
1241
Novavax
NVAX
$1.34B
| $69K | ﹤0.01% |
380
-666
| -64% | -$121K |
|
1242
Ultragenyx Pharmaceutical
RARE
$3.01B
| $69K | ﹤0.01% |
609
-296
| -33% | -$33.5K |
|
|
CCXI
1243
DELISTED
ChemoCentryx, Inc.
CCXI
| $69K | ﹤0.01% |
1,351
-908
| -40% | -$46.4K |
|
1244
Insmed
INSM
$30.8B
| $68K | ﹤0.01% |
1,990
-1,328
| -40% | -$45.4K |
|
1245
Relay Therapeutics
RLAY
$710M
| $68K | ﹤0.01% |
1,981
+432
| +28% | +$14.8K |
|
1246
Twist Bioscience
TWST
$1.55B
| $68K | ﹤0.01% |
546
-382
| -41% | -$47.6K |
|
1247
BridgeBio Pharma
BBIO
$10.1B
| $68K | ﹤0.01% |
1,103
-1,044
| -49% | -$64.4K |
|
1248
Fate Therapeutics
FATE
$118M
| $68K | ﹤0.01% |
822
-576
| -41% | -$47.7K |
|
|
IGMS
1249
DELISTED
IGM Biosciences
IGMS
| $68K | ﹤0.01% |
890
+6
| +0.7% | +$458 |
|
1250
Karyopharm Therapeutics
KPTI
$57.6M
| $67K | ﹤0.01% |
422
-135
| -24% | -$21.4K |
|